David Taussig

Royal Marsden Hospital

H指数:31

被引数:5,118

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intensity of conditioning but not measurable residual disease status impacts the outcomes of umbilical cord blood transplantation

预处理强度而非可测量微小残留病状态影响脐带血移植的结局

Blood Advances

IF7.1

2026-03-020

OAAI

Response to Qian et al

对钱等人的回应

Blood Advances

IF7.1

2026-02-260

OAAI

Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort

Olutasidenib治疗IDH1突变急性髓系白血病: 2期关键队列的最终五年结果

Journal of Hematology & Oncology

IF40.4

2025-11-170

OAAI

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy

BLOOD ADVANCES

IF7.1

2024-10-250

OAAI

Othman, Jad; Hwang, Angela; Brodermann, Maximillian; Abdallah, Islam; Mccloskey, Kayleigh; Gallipoli, Paolo; Clarke, Georgina; Dang, Raymond; Vidler, Jennifer; Krishnamurthy, Pramila; Basheer, Faisal; Latif, Anne-Louise; Palanicawandar, Renuka; Taylor, Tom; Khan, Asra; Campbell, Victoria; Hogan, Francesca; Kanellopoulos, Alex; Fleming, Kathryn; Collins, Angela; Dalley, Chris; Loke, Justin; Marshall, Scott; Taussig, David; Munisamy, Sreetharan; Loizou, Eleana; Yassin, Heba; Dennis, Mike; Zhao, Rui; Belsham, Edward; Murray, Duncan; Fowler, Nicole; Nions, Jenny; Khan, Anjum; Sellar, Rob; Dillon, Richard

A dual-channel electrochemical biosensor enables concurrent detection of pathogens and antibiotic resistance

BIOSENSORS & BIOELECTRONICS

IF10.5

2024-08-011

PRE

Maternal Immunization During the Second Trimester with BNT162b2 mRNA Vaccine Induces a Robust IgA Response in Human Milk: A Prospective Cohort Study (vol 118, pg 572, 2023)

AMERICAN JOURNAL OF CLINICAL NUTRITION

IF6.9

2023-11-010

OAAI

Maternal Immunization During the Second Trimester with BNT162b2 mRNA Vaccine Induces a Robust IgA Response in Human Milk: A Prospective Cohort Study

AMERICAN JOURNAL OF CLINICAL NUTRITION

IF6.9

2023-09-011

OAAI

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial

LEUKEMIA

IF13.4

2023-08-216

OAAI

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

LEUKEMIA

IF13.4

2023-08-0920

OAAI

Othman, Jad; Potter, Nicola; Mokretar, Katya; Taussig, David; Khan, Anjum; Krishnamurthy, Pramila; Latif, Anne-Louise; Cahalin, Paul; Aries, James; Amer, Mariam; Belsham, Edward; Conneally, Eibhlin; Craddock, Charles; Culligan, Dominic; Dennis, Mike; Duncan, Caroline; Freeman, Sylvie D.; Furness, Caroline; Gilkes, Amanda; Gkreka, Paraskevi; Hodgson, Katherine; Ingram, Wendy; Jain, Manish; King, Andrew; Knapper, Steven; Kottaridis, Panagiotis; McMullin, Mary Frances; Mohite, Unmesh; Ngu, Loretta; O'Nions, Jenny; Patrick, Katharine; Rider, Tom; Roberts, Wing; Severinsen, Marianne Tang; Storrar, Neill; Taylor, Tom; Russell, Nigel H.; Dillon, Richard

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

Olutasidenib (FT-2102) 可诱导复发或难治性IDH1-mutated AML患者持久完全缓解

BLOOD ADVANCES

IF7.1

2023-06-3048

OAAI

de Botton, Stephane; Fenaux, Pierre; Yee, Karen; Recher, Christian; Wei, Andrew H.; Montesinos, Pau; Taussig, David C.; Pigneux, Arnaud; Braun, Thorsten; Curti, Antonio; Grove, Carolyn; Jonas, Brian A.; Khwaja, Asim; Legrand, Ollivier; Peterlin, Pierre; Arnan, Montserrat; Blum, William; Cilloni, Daniela; Hiwase, Devendra K.; Jurcic, Joseph G.; Krauter, Juergen; Thomas, Xavier; Watts, Justin M.; Yang, Jay; Polyanskaya, Olga; Brevard, Julie; Sweeney, Jennifer; Barrett, Emma; Cortes, Jorge

A global study for acute myeloid leukemia with RARG rearrangement

BLOOD ADVANCES

IF7.1

2023-06-2812

OAAI

Zhu, Hong-Hu; Qin, Ya-Zhen; Zhang, Zhang-Lin; Liu, Yong-Jing; Wen, Li-Jun; You, M. James; Zhang, Cheng; Such, Esperanza; Luo, Hong; Yuan, Hong-Jian; Zhou, Hong-Sheng; Liu, Hong-Xing; Xu, Reng; Li, Ji; Li, Jian-Hu; Hao, Jian-Ping; Jin, Jie; Yu, Liang; Zhang, Jing-Ying; Liu, Li-Ping; Zhang, Le-Ping; Huang, Rui-Bin; Shen, Shu-Hong; Gao, Su-Jun; Wang, Wei; Yan, Xiao-Jing; Zhang, Xin-You; Du, Xin; Chu, Xiao-Xia; Yu, Yan-Fang; Wang, Yi; Mi, Ying-Chang; Lu, Ying; Cai, Zhen; Su, Zhan; Taussig, David Christopher; MacMahon, Suzanne; Ball, Edward D.; Wang, Huan-You; Welch, John S.; Yin, C. Cameron; Borthakur, Gautam; Sanz, Miguel A.; Kantarjian, Hagop M.; Huang, Jin-Yan; Hu, Jiong; Chen, Su-Ning

Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation

BLOOD ADVANCES

IF7.1

2023-06-055

OAAI

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes

Signal Transduction and Targeted Therapy

IF52.7

2023-02-270

OAAI

Longitudinal kinetics of RBD plus antibodies in COVID-19 recovered patients over 14 months

PLOS PATHOGENS

IF4.9

2022-06-037

OAAI

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

BLOOD ADVANCES

IF7.1

2022-04-1252

OAAI

Konopleva, Marina Y.; Roellig, Christoph; Cavenagh, Jamie; Deeren, Dries; Girshova, Larisa; Krauter, Juergen; Martinelli, Giovanni; Montesinos, Pau; Schaefer, Jonas A.; Ottmann, Oliver; Petrini, Mario; Pigneux, Arnaud; Rambaldi, Alessandro; Recher, Christian; Rodriguez-Veiga, Rebeca; Taussig, David; Vey, Norbert; Yoon, Sung-Soo; Ott, Marion; Muehlbauer, Susanne; Beckermann, Benjamin M.; Catalani, Olivier; Genevray, Magali; Mundt, Kirsten; Jamois, Candice; Fenaux, Pierre; Wei, Andrew H.

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

BLOOD ADVANCES

IF7.1

2022-04-0151

OAAI

Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence

NATURE COMMUNICATIONS

IF15.7

2021-09-1723

OAAI

AUTOIMMUNE DISEASE When a virus lies in wait

ELIFE